DB-006 / Derm-Biome Pharmaceuticals - LARVOL DELTA

Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs (GlobeNewswire) - "In a well-established preclinical model that closely replicates human AD, DB-006 significantly lowered inflammation and outperformed leading AD treatments ZORYVE (roflumilast) and VTAMA (tapinarof) in reducing itch symptoms, epithelial thickening, and IgE production. DB-006 has consistently demonstrated a highly favorable safety profile. Additionally, DB-006 exhibits antimicrobial activity against Staphylococcus aureus (S. aureus)."

Preclinical • Atopic Dermatitis

Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs (GlobeNewswire) - "In a well-established preclinical model that closely replicates human AD, DB-006 significantly lowered inflammation and outperformed leading AD treatments ZORYVE (roflumilast) and VTAMA (tapinarof) in reducing itch symptoms, epithelial thickening, and IgE production. DB-006 has consistently demonstrated a highly favorable safety profile...Additionally, DB-006 exhibits antimicrobial activity against Staphylococcus aureus (S. aureus). Up to 90% of people with AD are colonized by this bacterium, compared to only 10–20% of the general population. S. aureus overgrowth triggers inflammation, exacerbates itching, and is a primary driver of eczema flares. Notably, most topical non-steroidal AD drugs lack this antimicrobial activity."

Preclinical • Atopic Dermatitis